Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expected to Earn Q1 2024 Earnings of ($0.07) Per Share

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – Analysts at Zacks Small Cap issued their Q1 2024 EPS estimates for shares of Brainstorm Cell Therapeutics in a report issued on Thursday, April 11th. Zacks Small Cap analyst D. Bautz anticipates that the biotechnology company will post earnings of ($0.07) per share for the quarter. The consensus estimate for Brainstorm Cell Therapeutics’ current full-year earnings is ($0.47) per share. Zacks Small Cap also issued estimates for Brainstorm Cell Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.07) EPS and FY2026 earnings at ($0.24) EPS.

Separately, StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a research note on Wednesday, March 27th. They issued a “sell” rating for the company.

Brainstorm Cell Therapeutics Price Performance

BCLI opened at $0.58 on Monday. The firm has a fifty day moving average price of $0.45 and a 200 day moving average price of $0.31. Brainstorm Cell Therapeutics has a 1 year low of $0.13 and a 1 year high of $3.37. The stock has a market cap of $39.91 million, a P/E ratio of -1.42 and a beta of 0.28.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its position in Brainstorm Cell Therapeutics by 739.2% during the first quarter. Tower Research Capital LLC TRC now owns 8,862 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 7,806 shares during the period. State Street Corp raised its position in Brainstorm Cell Therapeutics by 10.8% during the first quarter. State Street Corp now owns 96,060 shares of the biotechnology company’s stock worth $323,000 after acquiring an additional 9,357 shares during the period. BlackRock Inc. raised its position in Brainstorm Cell Therapeutics by 2.4% during the second quarter. BlackRock Inc. now owns 485,464 shares of the biotechnology company’s stock worth $1,000,000 after acquiring an additional 11,372 shares during the period. Jane Street Group LLC acquired a new position in Brainstorm Cell Therapeutics during the second quarter worth $33,000. Finally, XTX Topco Ltd acquired a new position in Brainstorm Cell Therapeutics during the first quarter worth $40,000. 14.33% of the stock is currently owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.